Lessons To Be Learned: The Molecular Basis of Kinase‐Targeted Therapies and Drug Resistance in Non‐Small Cell Lung Cancer,Angewandte Chemie International Edition

当前位置： X-MOL 学术 › Angew. Chem. Int. Ed. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Lessons To Be Learned: The Molecular Basis of Kinase‐Targeted Therapies and Drug Resistance in Non‐Small Cell Lung Cancer
Angewandte Chemie International Edition ( IF 16.1 ) Pub Date : 2018-01-12 , DOI: 10.1002/anie.201710398
Jonas Lategahn ₁ , Marina Keul ₁ , Daniel Rauh ₁

Affiliation

The treatment of non‐small cell lung cancer (NSCLC) is currently experiencing a revolution. Over the last decade, the knowledge gained about the biochemical features of biomarkers and their predictive abilities has led to the development of targeted small‐molecule inhibitors that present an alternative to harsh chemotherapy. The use of these new therapies has improved the quality of life and increased the survival of patients. The occurrence of inevitable drug resistance requires the constant development of precision medicine. The detailed understanding of the target biology and the search for innovative chemical approaches has encouraged investigations in this field. Herein, we review selected aspects of the molecular targets and present an overview of current topics and challenges in the rational development of small molecules to target NSCLC.

中文翻译：

经验教训：非小细胞肺癌的激酶靶向疗法的分子基础和耐药性

非小细胞肺癌（NSCLC）的治疗目前正在经历一场革命。在过去的十年中，有关生物标记物的生化特征及其预测能力的知识促成了针对性小分子抑制剂的开发，这些抑制剂可替代严酷的化学疗法。这些新疗法的使用改善了生活质量并增加了患者的存活率。不可避免的耐药性的发生需要精密医学的不断发展。对靶标生物学的详细理解和对创新化学方法的探索鼓励了该领域的研究。在这里，我们审查分子目标的选定的方面，并提出了当前主题和小分子靶向NSCLC的合理发展中的挑战的概述。

更新日期：2018-01-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11